Journal
JOURNAL OF CLINICAL PATHOLOGY
Volume 75, Issue 9, Pages 581-584Publisher
BMJ PUBLISHING GROUP
DOI: 10.1136/jclinpath-2021-208008
Keywords
MELANOMA; GENETICS; Melanocytes; Pathology; Molecular; SKIN
Categories
Funding
- Cancer Institute NSW
Ask authors/readers for more resources
PTEN is a crucial tumor suppressor protein and its mutations are frequently observed in various cancers. The interactions between PTEN and other molecules in melanoma can have either positive or negative effects on melanoma pathogenesis.
PTEN is a well-known tumour suppressor protein that is frequently found to be mutated, inactivated or deleted in a wide range of different cancers. Its tumour suppressive properties result predominantly from its inhibitory effects on the PI3K-AKT signalling pathway. In melanoma, numerous different PTEN mutations have been identified in both melanoma cell lines and melanoma tissue. A number of different molecules can act on PTEN to either promote its suppression of melanoma, while other molecules may antagonise PTEN to inhibit its mechanism of action against melanoma. This review will discuss how the interactions of PTEN with other molecules may have a positive or negative impact on melanoma pathogenesis, giving rise to the potential for PTEN-targeted therapies against melanoma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available